Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22454527 | 0.80 | MEN1 (0.41) | MEN1KMT2AOXTRHPGDSLC6A3 | |
| SCHEMBL28741465 | 0.80 | MEN1 (0.41) | MEN1KMT2AOXTRHPGDSLC6A3 | |
| SCHEMBL9508809 | 0.78 | MGLL (0.44) | MEN1KMT2AOXTRAVPR1A | |
| SCHEMBL10677822 | 0.76 | MGLL (0.43) | MEN1KMT2AOXTRAVPR1A | |
| SCHEMBL23817377 | 0.72 | SLC18A3 (0.50) | MEN1KMT2AHPGDSLC6A3 | |
| Benzoic Acid SCHEMBL28591606 | 0.72 | MEN1 (0.56) | MEN1KMT2AHPGDSLC6A3EP300 | |
| SCHEMBL9506049 | 0.72 | MEN1 (0.46) | MEN1KMT2AOXTRAVPR1A | |
| SCHEMBL4776765 | 0.71 | MEN1 (0.52) | MEN1KMT2AHPGDSLC6A3EP300 | |
| SCHEMBL4082004 | 0.71 | GSTP1 (0.49) | MEN1KMT2AHPGDSLC6A3 | |
| SCHEMBL11020227 | 0.71 | OXTR (0.40) | MEN1KMT2AOXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2011106632-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | MEN1 3689/4885KMT2A 137/4885OXTR 4281/4885 |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | MEN1 3689/4885KMT2A 137/4885OXTR 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.